Free weekly newsletter
Get the free weekly contract digest
The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Aquestive Therapeutics Extends Marketing Approval Deadline and Issues Warrant to RTW Investments
Mar 04, 2026•3 months ago
Contract Type
purchase_agreement
WarrenBiotechnologyHealthcareHealth CareMedicalTherapeuticsPharmaceuticalBiopharmaDescription
On March 3, 2026, Aquestive Therapeutics, Inc. entered into an amendment to extend the Marketing Approval Deadline of a prior Purchase and Sale Agreement with RTW Investments to June 30, 2027. Additionally, the company agreed to issue a warrant to purchase 375,000 shares of its common stock at an exercise price of $4.00 per share, expiring on March 3, 2029. These agreements highlight the ongoing collaboration between Aquestive and RTW.
Related People
Suggested for you
Agreement Insights
Based on industry dataContract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months